May 28, 2020
A group of pharmaceutical companies, including Bausch Health Co., has urged a California federal judge not to certify a class of buyers claiming the companies violated federal antitrust law by blocking a generic version of the diabetes drug Glumetza from entering the market.
March 06, 2020
A California federal judge has refused to dismantle a lawsuit alleging Bausch Health Co. and other pharmaceutical companies violated federal antitrust law by blocking a generic version of diabetes drug Glumetza through a reverse pay-for-delay scheme, but trimmed indirect buyers' federal antitrust claims.